Astaxanthin is a Novel Candidate for Glioblastoma Treatment? A Review

Area of Science:

• Oncology
• Natural Product Chemistry
• Pharmacology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis and high recurrence rates.
• Current GBM treatments offer limited survival benefits and cannot achieve a complete cure.
• Developing effective therapies is challenging due to tumor recurrence and treatment resistance.

Purpose of the Study:

• To review the potential of astaxanthin (AXT) as a novel therapeutic agent for glioblastoma.
• To summarize current research on AXT's effects on GBM cells and animal models.
• To highlight AXT's role in developing innovative cancer treatments.

Main Methods:

• Literature review of studies investigating astaxanthin's effects on glioblastoma.
• Analysis of in vitro and in vivo data on AXT's impact on GBM.
• Focus on AXT's mechanisms of action, including targeting reactive oxygen species (ROS).

Main Results:

• Astaxanthin (AXT) demonstrates significant impact on glioblastoma cells in laboratory and animal studies.
• AXT has been shown to target reactive oxygen species (ROS), a key factor in cancer progression.
• Evidence suggests AXT suppresses tumor growth under both in vitro and in vivo conditions.

Conclusions:

• Astaxanthin (AXT) exhibits considerable potential as a therapeutic option for glioblastoma (GBM).
• AXT's ability to target ROS and inhibit tumor growth makes it a promising candidate for novel GBM therapies.
• Further research into AXT may lead to innovative treatment strategies for glioblastoma.